Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Glycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL30710214 | 1.00 | LMNA (0.64) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL31106042 | 1.00 | LMNA (0.64) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL888512 | 1.00 | LMNA (0.64) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL579432 | 1.00 | LMNA (0.64) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL21101 | 1.00 | LMNA (0.64) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL468814 | 0.97 | LMNA (0.60) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL1792712 | 0.97 | LMNA (0.60) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL14482187 | 0.97 | LMNA (0.60) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL14482185 | 0.97 | LMNA (0.60) | LMNAALDH1A1THRBGABRR1GABBR2 | |
| Glycerin SCHEMBL9332836 | 0.97 | LMNA (0.60) | LMNAALDH1A1THRBGABRR1GABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107109441-A | The fermentation process that glycerine and acetic acid conversion are improved | 帝斯曼知识产权资产管理有限公司 | 2017-08-29 | — | — | CN | claimed |
| CN-105492599-A | Glycerol and acetic acid converting yeast cells with improved acetic acid conversion | DSM IP ASSETS BV | 2016-04-13 | — | — | CN | claimed |
| EP-1135401-B1 | GLYCERYL NUCLEOTIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | SCHOTT HERBERT (DE) | 2003-06-18 | — | — | EP | claimed |
| EP-0350973-B1 | Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system | EHRENFELD UDO (DE) | 1997-11-05 | — | — | EP | claimed |
| US-5021234-A | Agent and product for the diagnosis and treatment of tumors and for the treatment of weaknesses of the cellular and humoral immune defense | EHRENFELD UDO (DE) | 1991-06-04 | — | — | US | claimed |
| JP-10215895-A | — | — | None | — | — | JP | disclosed |
| CN-120350456-A | Antibacterial flame-retardant polylactic acid DTY filament and preparation method thereof | 绍兴迈宝科技有限公司 | 2025-07-22 | — | — | CN | disclosed |
| CN-120154725-A | Application of transketolase inhibitor targeting macrophages in preparation of drugs for preventing and treating fatty liver | 四川省医学科学院·四川省人民医院 | 2025-06-17 | — | — | CN | disclosed |
| CN-119913079-A | Streptomyces LZZY-S3 and application thereof | 柳州职业技术大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-119700984-A | Application of macrophage transketolase targeted inhibitor in preparation of medicines for preventing and treating inflammatory diseases | 四川省医学科学院·四川省人民医院 | 2025-03-28 | — | — | CN | disclosed |
| EP-4455081-A1 | INDUSTRIAL PROCEDURE FOR OBTAINING IRON-LITHIUM PHOSPHATE | De la Cámara Delgado, María de las Mercedes (ES) | 2024-10-30 | — | — | EP | disclosed |
| CN-112669904-B | Screening method for phosphoglycerate kinase and substrate binding mode | 中国科学院大连化学物理研究所 | 2024-03-01 | — | — | CN | disclosed |
| US-6168778-B1 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes | NEXSTAR PHARMACEUTICALS, INC. | 2001-01-02 | — | — | US | disclosed |
| EP-1029551-A2 | Nitrogen monoxide metabolite-polyoxyalkylene-hemoglobin complex | HOKKAIDO UNIVERSITY (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-6051698-A | ARTIFICIAL LIGAND INCLUDES 2'FLUORO MODIFIED NUCLEOTIDES; FOR ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS AGAINST KARPOSI'S SARCOMA, TREATMENT OF MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF COLORADO, SUCCESSOR IN INTEREST TO UNIVERSITY RESEARCH CORPORATION AND/OR UNIVERSITY LICENSE EQUITY HOLDINGS, INC. | 2000-04-18 | — | — | US | disclosed |
| CN-1248245-A | Friable compounds for pathogen inactivation | CERUS CORP (US) | 2000-03-22 | — | — | CN | disclosed |
| EP-0957929-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| JP-H10215895-A | MEASUREMENT OF ACTIVITY OF CREATINE PHOSPHOKINASE AND REAGENT THEREFOR | INTERNATL REAGENTS CORP | 1998-08-18 | — | — | JP | disclosed |
| WO-1998018480-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
| US-5021234-A | Agent and product for the diagnosis and treatment of tumors and for the treatment of weaknesses of the cellular and humoral immune defense | EHRENFELD UDO (DE) | 1991-06-04 | — | — | US | disclosed |